



*Atoms for Peace and Development*

الوكالة الدولية للطاقة الذرية  
国际原子能机构  
International Atomic Energy Agency  
Agence internationale de l'énergie atomique  
Международное агентство по атомной энергии  
Organismo Internacional de Energía Atómica

Vienna International Centre, PO Box 100, 1400 Vienna, Austria  
Phone: (+43 1) 2600 • Fax: (+43 1) 26007  
Email: [Official.Mail@iaea.org](mailto:Official.Mail@iaea.org) • Internet: <https://www.iaea.org>

National Liaison Officers/National Coordinators

In reply, please refer to: **SP-TC-RER6041-2500772**  
Dial directly to extension: (+43 1) 2600-25981

2025-03-12

**Subject: TC Sponsored Participation on Treatment of Metastatic Bone Pain Using Bone-Seeking Agents from 10 to 11 April**

Dear National Liaison Officer / National Coordinator,

I am pleased to inform you that the International Atomic Energy Agency (IAEA) is organizing the above event under the IAEA technical cooperation project RER6041, "Enhancing and Harmonizing Nuclear Medicine and Diagnostic Imaging Capabilities".

The purpose of the workshop is to lecture participants in Pathophysiology and medical treatment of bone pain, Pro/con alpha/beta emitters, performing of dosimetry and Combination treatment to improve the therapeutic effect.

Selection of participants will be in accordance with IAEA procedures. Member States are strongly encouraged to identify women participants.

The IAEA will provide non-local participants with a round-trip air ticket based on the most direct and economical route between the airport nearest the participant's residence and Vienna or a travel allowance to purchase an air ticket. Travel details will be agreed with the participants upon receipt of their official nomination. Participants will also receive an allowance from the IAEA sufficient to cover their costs of lodging, daily subsistence and miscellaneous expenses for the duration of the event in line with IAEA rules and procedures.

We would appreciate receiving your country's nominations by 17 March 2025 through the IAEA's InTouch+ platform (<https://Intouchplus.iaea.org>). Should this not be possible, applicants may download the Nomination Form for the course from the IAEA's webpage. Completed forms must be endorsed by the relevant government authority and may be sent to the IAEA, preferably by email to Official Mail - IAEA Mail address [Official.Mail@iaea.org](mailto:Official.Mail@iaea.org), with copy to Ms Sibel Unlu [s.unlu@iaea.org](mailto:s.unlu@iaea.org) and Ms Angie Mieses [A.Mieses-Concepcion@iaea.org](mailto:A.Mieses-Concepcion@iaea.org). Please be advised that late nominations or replacements of participants after the closing date for nominations will not be accepted.

We look forward to receiving your early response.

Yours sincerely,

A handwritten signature in blue ink, appearing to read 'Sibel', is positioned above the printed name.

Sibel Unlu  
Programme Management Officer  
Division for Europe  
Department of Technical Cooperation

Enclosure: Information Sheet



**The 4th International Congress Imaging infections and inflammation  
under the Regional TC Project RER/6/041**

<b>Event Number</b>	SP-TC-RER6041- EVT2500772
<b>Event Title</b>	TC Sponsored Participation on Treatment of Metastatic Bone Pain Using Bone-Seeking Agents
<b>Location</b>	Vienna, Austria
<b>Date</b>	10 to 11 April 2025
<b>Nomination Deadline</b>	17 March 2025
<b>Event Information</b>	<p>This course provides a comprehensive overview of the Internal radiotherapy with bone-seeking agents is effective in delivering high doses of radiation to widespread metastatic bone lesions and may limit the radiation absorbed dose to healthy tissue. Beta emitter have long been preferred agents for bone pain palliation. The approval of <math>^{223}\text{Ra}</math> and data showing a prolonged survival with alpha emitter are favoured in bone pain palliation. Unfortunately, we do not have good data on the survival after treatment with beta emitters. In the face-to-face course we will discuss the pathophysiology of bone pain to understand the principle of therapeutic effect of bone seeking agents. Dosimetry is essential to increase the dose to the tumour by limiting of severe side effects. All the focus is on the alpha emitters only, based on the poor data about survival data for the beta emitters. The future of therapy in Nuclear Medicine is the combination with other agents to improve the therapeutic effect, e.g. chemotherapy, immunotherapy or anti-androgen therapy.</p> <p><b>LEARNING OBJECTIVES</b></p> <ul style="list-style-type: none"> <li>• Pathophysiology and medical treatment of bone pain</li> <li>• Pro/con alpha/beta emitters</li> <li>• Performing of dosimetry</li> <li>• Combination treatment to improve the therapeutic effect</li> </ul>
<b>Organizer</b>	<p>European School of Multimodality Imaging &amp; Therapy</p> <p>Link: <a href="#">Treatment of Metastatic Bone Pain Using Bone-Seeking Agents - The European School of Multimodality Imaging &amp; Therapy (ESMIT)</a></p>
<b>Selection Criteria</b>	Nuclear medicine physician, junior or senior, with an interest in treatment